Latest News for: fda

Edit

Trump’s New $2B WHO, FDA Walks Back Food Dye Ban & The US Gov’s Long-Documented ...

The Last American Vagabond 24 Feb 2026
Anyone telling you what the Read More ....
Edit

Trump's New $2B WHO, FDA Walks Back Food Dye Ban & The US Gov's Long-Documented ...

Rumble 24 Feb 2026
Click the Rumble article link to see the video ....
Edit

FDA proposes new system for approving customized drugs and therapies for rare diseases

Weatherford Democrat 24 Feb 2026
....
Edit

FDA cracks down on weight-loss drug alternatives as thousands sickened in Maryland

The Brunswick News 24 Feb 2026
BALTIMORE — Popular weight-loss drugs, including ...
Edit

How Trump’s FDA is breaking his promise to America’s patients

New York Post 24 Feb 2026
FDA reverses decision not to review Moderna’s new flu vaccine ... An estimated 30 million Americans have one or more rare disorders, 95% of which have no FDA-approved treatment ... The FDA told Moderna it was OK with its clinical trial design.
Edit

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of (MacroGenics Inc)

Public Technologies 24 Feb 2026
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ... Under the partial clinical hold, no new patients will be enrolled in the LINNET study until the partial hold is lifted by the FDA.
Edit

FDA’s latest infant food RECALL reveals gaping holes in food safety as industry giants profit ...

Natural News 23 Feb 2026
Initiative Foods’ Tippy Toes Apple Pear Banana Fruit Puree was recalled after FDA testing found dangerously high levels of patulin, a neurotoxic... .
Edit

U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status

Caledonian Record 23 Feb 2026
-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data -- ....
Edit

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for ...

Nasdaq Globe Newswire 23 Feb 2026
PDUFA action date set for August 23, 2026 ... .
Edit

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies ...

Nasdaq Globe Newswire 23 Feb 2026
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04. Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 ... .
Edit

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for ...

Nasdaq Globe Newswire 23 Feb 2026
Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer ... .
Edit

Dar� Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a ...

Nasdaq Globe Newswire 23 Feb 2026
... major unmet need with no FDA-approved therapies.
Edit

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License

Enid News & Eagle 23 Feb 2026
PDUFA action date set for August 23, 2026 ... .
Edit

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a

Enid News & Eagle 23 Feb 2026
SAN DIEGO, Feb ... (NASDAQ ... Food and .
Edit

Vanda Pharmaceuticals (VNDA) Stock: Jumps 44% After FDA Approves Second Drug in Two Months

BitRSS 23 Feb 2026
TLDR FDA approved BYSANTI (milsaperidone) for ...

Article Search

tools
×
×
×
×